In the first quarter of 2024, Novartis increased sales by ten percent from 10.8 billion dollars in the previous year to around 11.8 billion dollars. At constant exchange rates, growth even amounted to eleven per cent. Volume increases of 14 percentage points had a positive impact on sales development. Competition from...
Novartis closed both the fourth quarter and the financial year in the new constellation of its continuing operations with solid growth in sales, operating income and profit. Net sales in the fourth quarter amounted to 11.4 billion dollars, an increase of eight percent. The result was characterized by volume increases...
The Swiss pharmaceutical company Novartis has presented the results for the third quarter of 2023. Thus, net sales increased by twelve percent to $11.8 billion. Net income is $1.5 billion, an increase of 14 percent. These are the first quarterly figures announced by the pharmaceutical company without its spun-off...
Novartis has signed an agreement to acquire Chinook Therapeutics. Chinook Therapeutics is a Seattle-based biopharmaceutical company in clinical-stage development of two high-value drugs for rare, severe chronic kidney disease. Approval results for one of the compounds are expected in the fourth quarter of 2023. The...
Novartis reported fourth-quarter 2022 sales of $12.7 billion. This represents a decrease of four percent compared to the same period last year, when $13.2 billion was generated. At constant exchange rates, there was an increase of three percent. The period was characterized by volume increases partially absorbed by...
Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort. The new lab aims to bolster Novartis AI capabilities from research through commercialization and help accelerate the discovery...
